Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Zhijie Wang(Hubei University of Medicine), Lei Nie(Shandong University), Diansheng Zhong(Tianjin Medical University General Hospital), Caicun Zhou(Tongji University), Buhai Wang(Northern Jiangsu People's Hospital), Qiming Wang(Henan Cancer Hospital), Jiuwei Cui(Jilin University), Zhenzhou Yang(Dalian Medical University), Xiaohong Wu(Soochow University), Jianjin Huang(Second Affiliated Hospital of Zhejiang University), Ying Cheng(Jilin Province Tumor Hospital), Dongqing Lv(Wenzhou Medical University), Yuming Jia(Second People’s Hospital of Yibin), Dong Wang(Army Medical University), Anwen Liu(Nanchang University), Sheng Hu(Hubei Cancer Hospital), Liyun Miao(Nanjing Drum Tower Hospital), Guogui Sun(Tangshan People's Hospital), Qisen Guo(Shandong Tumor Hospital), Lin Wu(Materials Systems (United States)), Yingyi Wang(Shanghai Jiao Tong University), Wei Zhang(Nanchang University), Xiaoling Li(University of Science and Technology of China), Hu Liu(Anhui Provincial Hospital), Zhihong Zhang(Jiangsu Province Hospital), Qiang Li(Chongqing University), Yong Song(Nanjing General Hospital of Nanjing Military Command), Zhuang Yu(Shanghai East Hospital), Baohui Han(Shanghai Chest Hospital), Yun Fan(Zhejiang Cancer Hospital), Meiqi Shi(Jiangsu Cancer Hospital), Jianhua Shi(Linyi People's Hospital), Hui Zhao(Dalian Medical University), Xiuwen Wang(Second Hospital of Shandong University), Mei Ji(The First People's Hospital of Changzhou), Xiaoli Zhu(Tongji University), Zhigang Han, Baolan Li(Capital Medical University), Ziping Wang(University of Science and Technology of China), Xicheng Wang(Shandong University of Traditional Chinese Medicine), Xingya Li(Zhengzhou University), Yan Yu(Binzhou Medical University), Jingxun Wu(First Affiliated Hospital of Xiamen University), Xiaodong Zhang(Shanghai Jiao Tong University), Jiaqi Yang(Second Affiliated Hospital of Guangzhou Medical University), Yunpeng Liu(Shenyang Institute of Automation), Beili Gao(Ruijin Hospital), Shaozhang Zhou(Tumor Hospital of Guangxi Medical University), Liang Han(Tianjin Medical University Cancer Institute and Hospital), Youxin Ji(Qingdao University)
Journal of Clinical Oncology
October 7, 2022
10.1200/jco.22.00727
Cited by 177

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k